Therefore, targeting AR signaling by androgen deprivation therapy (ADT) is a mainstay for pharmacological treatment of men diagnosed with PC at an advanced stage or experiencing tumor recurrence after surgery (2, 3). This evidence concerns the gene AR and pachyonychia congenita.